Skip to main content
Search
Search
Advanced Search
Skip main navigation
Free access
Editorial
12 July 2017

Deriving more value from RWE to ensure timely access of medicines by patients

Authors: Sarah Wamala Andersson [email protected] and Mattias KyhlstedtAuthor Info & Affiliations
Publication: J. Comp. Eff. Res.
Volume 6, Number 5
https://doi.org/10.2217/cer-2017-0030
PDFFormats
First page of PDF

Formats available

You can view the full content in the following formats:

View PDFView Full Text

References

1.
De Lusignan S, Crawford L, Munro N. Creating and using real-world evidence to answer questions about clinical effectiveness. J. Innov. Health Inform. 22(3), 368–373 (2015).
PubMed
Google Scholar
2.
Looney W. Real world evidence – from volume to value. Pharmaceutical Executive 36, 10 (2016).
Google Scholar
3.
Emilsson L, Lindahl B, Köster M et al. Review of 103 Swedish healthcare registries. J. Intern. Med. 277, 94–136 (2014).
PubMed
Google Scholar
5.
Muka T, Imo D, Jaspers L et al. The global impact of non-communicable diseases on healthcare spending and national income: a systematic review. Eur. J. Epidemiol. 30(4), 251–277 (2015).
PubMed
Google Scholar
6.
Hughes B, Kessler M. The $1 billion real world evidence. IMS Health (2014). www.imshealth.com/files/web/Global/Services/Services%20TL/rwes_breaking_new_ground_d10.pdf.
Google Scholar
7.
Czirakym M, Pollock M. Real world evidence studies. Applied Clinical Trials (2015). www.appliedclinicaltrialsonline.com/real-world-evidence-studies?pageID=2.
Google Scholar
8.
Sherman RE, Anderson SA, Dal Pan GJ et al. Real-world evidence – what is it and what can it tell us? N. Engl. J. Med. 375(23), 2293–2297 (2016).
PubMed
Google Scholar
9.
Petrova M, Dale J, Fulford BK. Values-based practice in primary care: easing the tensions between individual values, ethical principles and best evidence. Br. J. Gen. Pract. 56(530), 703–709 (2006).
PubMed
Google Scholar
10.
Brown MM, Brown GC. Update on value-based medicine. Curr. Opin. Ophthalmol. 24, 183–189 (2013).
PubMed
Google Scholar
11.
Ludvigsson JF, Andersson E, Ekbom A et al. External review and validation of the Swedish national inpatient register. BMC Public Health 11, 450 (2011).
PubMed
Google Scholar
12.
Trojano T, Tintore M, Montalban X et al. Treatment decisions in multiple sclerosis – insights from real-world observational studies. Nat. Rev. Neurol. 13(2), 105–118 (2017).
PubMed
Google Scholar
13.
Synergus. Where is the best quality real world data regarding heart failure in Europe. https://synergus.com/blog/where-best-quality-real-world-data-regarding-heart-failure-europe.
Google Scholar
14.
Anderson SR, Auquier A, Hauck WW et al. Statistical Methods for Comparative Studies: Techniques for Bias Reduction. Wiley & Sons, NJ, USA (2009).
Google Scholar
15.
Stel VS, Dekker FW, Zoccali C, Jager KJ. Instrumental variable analysis. Nephrol. Dial. Transplant. 28(7), 1694–1699 (2013).
PubMed
Google Scholar
16.
Garavan T. Global talent management in science-based firms: an exploratory investigation of the pharmaceutical industry during the global downturn. Int. J. Human Res. Management 23, 12 (2012).
Google Scholar
17.
Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N. Engl. J. Med. 342(25), 1887–1892 (2000).
PubMed
Google Scholar
18.
Thygesen LC, Ersboll AK. When the entire population is the sample: strengths and limitations in register-based epidemiology When the entire population is the sample: strengths and limitations in register-based epidemiology. Eur. J. Epidemiol. 29, 551–558 (2014).
PubMed
Google Scholar
19.
Hall D. Why public–private partnerships don't work. Public Services International (2015). www.world-psi.org/sites/default/files/rapport_eng_56pages_a4_lr.pdf.
Google Scholar
20.
Gill JL, Avouac B, Duncombe R et al. The use of real world evidence in the European context: an analysis of key expert opinion. London School of Economics (2016). http://blogs.lse.ac.uk/lseenterprise/files/2016/12/RWE_in_Europe_Paper1.pdf.
Google Scholar
21.
Epstein RS, Sidorov J, Lehner JP, Salimi T. Integrating scientific and real-world evidence within and beyond the drug development process. J. Comp. Eff. Res. 1(Suppl. 1), 9–13 (2012).
Crossref
PubMed
Google Scholar
22.
Garrison L, Neumann P, Erickson P et al. Using real world data for coverage and payment decisions: the ISPOR real-world data task force report. Value Health 10(5), 326–335 (2007).
PubMed
Google Scholar
23.
Pietri G, Masoura P. Market access and reimbursement: the increasing role of real-world evidence. Value Health 17(7), A450–A451 (2014).
PubMed
Google Scholar
24.
Makady M, Ten Ham R, De Boer A et al. Policies for use of real-world data in health technology assessment (HTA): a comparative study of six HTA agencies. Value Health 20(4), 520–532 (2017).
PubMed
Google Scholar
25.
White R. Building trust in real-world evidence and comparative effectiveness research: the need for transparency. J. Comp. Eff. Res. 6(1), 5–7 (2017).
PubMed
Google Scholar
26.
Eichler HG, Baird HG, Barker R et al. From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients. Clin. Pharmacol. Ther. 97(3), 234–246 (2015).
PubMed
Google Scholar
|